leisure time -WSS

leisure time

author：fashion 2025-09-29 20:00:21 - browse：68

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Hospitals look to new technology to keep health care workers safe

explore

leisure time

WSS

Key Senate panel to consider PBM, drug pricing reform package

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Infant mortality in U.S. rose last year for first time in decades: CDC

Gene therapy’s promise and the high cost of hope

NYU radiologists take on the challenge of expensive MRI machines

Ransomware attacks on hospitals: Study outlines patient impact

leisure time

leisure time

Wikipedia

The high cost of giving birth even with insurance

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

In age of alternative facts, a scholarly course on calling out crap

After Sarepta trial failure, Duchenne families brace for more debate

As demand for Covid shots wanes, Moderna seeks its next success

In key trial, Verve's treatment lowers cholesterol levels in patients

BioMarin wins approval for gene therapy to treat hemophilia A

David Sabatini, ex

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Childhood cancer progress stalls for Black, Hispanic kids: Report

hotspot

All of Us, NIH's precision medicine initiative, gets a big boost

Childhood cancer progress stalls for Black, Hispanic kids: Report

Why medical students are struggling with mental health

Prime Medicine says its gene editing passes test in monkeys

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

leisure time

explore

leisure time

focus